JP Morgan Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and raises the price target from $50 to $54.
August 06, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Eric Joseph maintains an Overweight rating on Rocket Pharmaceuticals and raises the price target from $50 to $54.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence and positively impact the stock price of Rocket Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100